Johnson & Johnson
Change company Symbol lookup
Select an option...
JNJ Johnson & Johnson
PTI Proteostasis Therapeutics Inc
CALB California BanCorp
$NOPM2 Refinitiv Norway Metal & Mining Inde
EBAY eBay Inc
PTON Peloton Interactive Inc
GO Grocery Outlet Holding Corp
NUE Nucor Corp
SJM J M Smucker Co
KR Kroger Co
Go

Health Care : Pharmaceuticals | Large Cap Blend
Company profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Postmarket

Last Trade
Delayed
$144.06
0.19 (0.13%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$143.87
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
144.77
Day's Low
143.61
Volume
(Heavy Day)
Volume:
11,035,963

10-day average volume:
7,026,433
11,035,963

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Eli Lilly and Company - LLY

11:15 pm ET October 20, 2020 (PR Newswire) Print

Pomerantz LLP is investigating claims on behalf of investors of Eli Lilly and Company ("Eli Lilly" or the "Company") (NYSE: LLY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Eli Lilly and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On October 13, 2020. the National Institute of Allergy and Infectious Diseases recommended a pause on the trial evaluating adding Eli Lilly's antibody-based drug, LY-CoV555, to remdesivir for the treatment of COVID-19. That same day, Reuters reported that U.S. Food and Drug Administration ("FDA") inspectors "uncovered serious quality control problems" at the Company's plant that will manufacture COVID-19 drugs. The article reported that "[f]ollowing its November inspection, the FDA classified the problems as the most serious level of violation, resulting in an 'Official Action Indicated' (OAI) notice." Among other violations, the FDA "found that data on the plant's various manufacturing processes had been deleted and not properly audited."

On this news, Eli Lilly's stock price fell $4.41 per share, or 2.85%, to close at $150.08 per share on October 13, 2020.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:Robert S. WilloughbyPomerantz LLPrswilloughby@pomlaw.com888-476-6529 ext. 7980

https://c212.net/c/img/favicon.png?sn=DC65321&sd=2020-10-20

View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-eli-lilly-and-company---lly-301156428.html

SOURCE Pomerantz LLP

https://rt.prnewswire.com/rt.gif?NewsItemId=DC65321&Transmission_Id=202010202315PR_NEWS_USPR_____DC65321&DateId=20201020

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.